Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 4/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3376301 | 0.86 | LMNA (0.49) | ALDH1A1TSHRKDM4EHPGDRAB9A | |
| SCHEMBL3653448 | 0.82 | CNR2 (0.47) | ALDH1A1TSHRCNR2CNR1LMNA | |
| SCHEMBL9028491 | 0.82 | LMNA (0.63) | ALDH1A1TSHRCNR2CNR1CHRM1 | |
| SCHEMBL10086145 | 0.79 | ALDH1A1 (0.56) | ALDH1A1TSHRKDM4EHPGDRAB9A | |
| SCHEMBL4154426 | 0.78 | KDM4E (0.55) | ALDH1A1TSHRKDM4EHPGDRAB9A | |
| SCHEMBL4737409 | 0.76 | CNR2 (0.39) | ALDH1A1CNR2CNR1LMNAMAPT | |
| SCHEMBL6042188 | 0.75 | CNR2 (0.70) | ALDH1A1TSHRCNR2CNR1LMNA | |
| SCHEMBL5012269 | 0.72 | KDM4E (0.43) | ALDH1A1TSHRKDM4EHPGDRAB9A | |
| SCHEMBL27794869 | 0.71 | ALDH1A1 (0.72) | ALDH1A1TSHRKDM4EHPGDRAB9A | |
| SCHEMBL2053427 | 0.71 | CNR2 (0.55) | ALDH1A1TSHRCNR2CNR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | ALDH1A1 530/4885TSHR 4310/4885KDM4E 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.